Why a Second Opinion Comes Before You Search for Flights
This article is for men with metastatic castration-resistant prostate cancer (mCRPC) - cancer that has spread beyond the prostate and no longer responds to hormone-lowering treatment. If you are weighing Lu-177 PSMA therapy (lutetium Lu-177 vipivotide tetraxetan, sold as Pluvicto in the US and Europe) and India is on your shortlist for access or cost reasons, one step should come before any flight search: a remote eligibility review.
Lu-177 PSMA therapy targets a protein called PSMA (prostate-specific membrane antigen) on prostate cancer cells. A radioactive molecule attaches to that protein and delivers radiation directly to tumor cells. The therapy only works if your tumors carry enough PSMA. That is confirmed by a PSMA-PET scan - a specialized imaging test that maps PSMA expression across the body. If the scan shows low or absent PSMA, the treatment is unlikely to reach enough cancer cells to be useful.
Spending money on flights, visas, and accommodation - only to be told on arrival that your scans do not meet the threshold - is a real risk. A remote second opinion uses your existing scans and medical records. It can answer the eligibility question in days, not weeks, and it costs far less than the trip itself.
What Makes You Eligible: A Quick Checklist
Before a specialist team reviews your case, it helps to know what they are looking for. The five criteria below match the requirements used in the VISION trial - the phase 3 study that led to regulatory approval of lutetium Lu-177 vipivotide tetraxetan for mCRPC - and the indications published by the US Food and Drug Administration.
- PSMA-positive scan. At least one metastatic lesion must show PSMA uptake greater than normal liver on a 68Ga-PSMA-PET or an approved equivalent scan. No measurable lesion (a lymph node over 2.5 cm, a soft-tissue lesion over 1 cm, or a bone lesion with a soft-tissue component over 1 cm) should show uptake at or below liver level.
- Prior androgen receptor pathway inhibitor (ARPI) treatment. You should have received at least one ARPI such as enzalutamide or abiraterone, with documented disease progression on that treatment.
- Prior taxane chemotherapy - or a clinical reason to delay it. The original VISION trial approval required at least one prior taxane regimen. Expanded approvals now allow access for some patients who have not yet received taxane, if their oncologist considers it clinically appropriate to delay.
- Adequate organ function. Blood counts, kidney function, and liver function must meet minimum thresholds. Castrate testosterone level (below 50 ng/dL) is also required.
- Reasonable performance status. You need to be well enough to tolerate an intravenous infusion and short-term radiation precautions. Most trial protocols used an ECOG performance status of 0 or 1 as a guide.
If you are unsure where you stand on any of these, gather the documents listed in the next section. A remote review team can interpret them for you and flag which criteria may need clarification.
What the PSMA-PET Report Actually Shows
The PSMA-PET scan is the central piece of evidence in any eligibility review. A study comparing PSMA tracers in mCRPC patients showed that eligibility can shift depending on which tracer was used and how the radiologist interprets the images. Two common tracers are 68Ga-PSMA-11 and 18F-DCFPyL. Both are accepted, but their uptake characteristics differ slightly - meaning a nuclear medicine specialist familiar with both can make a real difference in borderline cases.
The core threshold is simple in principle: at least one lesion must light up more brightly than normal liver tissue. In practice, many scans sit in a gray zone. Lesions may be small. Some may show strong uptake while others show low uptake. Mixed scans - where some lesions are clearly PSMA-positive and others are not - are more common than most patients expect.
If your report uses phrases like "heterogeneous PSMA expression," "low-level uptake in some lesions," or "equivocal findings," that does not automatically disqualify you. But it does mean the scan needs review by a nuclear medicine physician who specializes in PSMA imaging, not just a general oncologist. For a full breakdown of how gray-zone results are assessed, see our article on borderline PSMA-PET results and Lu-177 eligibility.
If you do not yet have a PSMA-PET scan and want to understand what the report will tell you, our guide on what your PSMA-PET results mean for Lu-177 eligibility walks through the key terms and how the uptake scale is used in practice.
Documents to Gather Before Requesting a Review
A remote second opinion works because it draws on data you already have. The more complete your file, the faster and more accurate the review. Here is what to pull together:
- PSMA-PET scan images in DICOM format. DICOM is the raw digital file format for medical imaging. Ask your imaging center for the files on a USB drive or via a secure download link. A written report alone is not enough - the reviewer needs to see the actual scan images to assess individual lesion uptake.
- PSMA-PET written report. The radiologist's interpretation, including any SUVmax values (a measure of how brightly a lesion lights up) and descriptions of individual lesions where available.
- Treatment history summary. A list of every cancer treatment you have received, with approximate start and stop dates and the reason each was stopped. Include all hormone therapies and any chemotherapy regimens.
- Recent blood test results. Specifically: full blood count, creatinine or eGFR (estimated glomerular filtration rate, which measures kidney function), liver enzymes (ALT and AST), PSA, and testosterone. Results from the past six to eight weeks are most useful.
- Pathology report from biopsy. Your original diagnosis report, and any repeat biopsy if done at recurrence or progression.
- Prior imaging. CT scans, bone scans, or MRI that show the current extent of disease, especially if done alongside or shortly after the PSMA-PET.
You do not need all of these on day one. Start with the PSMA-PET images and your treatment summary. Most specialist teams can give a provisional eligibility flag from those two items and will request anything else they need.
How a Remote Eligibility Review Actually Works
Remote second opinions for Lu-177 PSMA eligibility are more straightforward than many patients expect. The process typically runs like this:
- You share your documents - usually via a secure file-transfer link or encrypted email - with the reviewing team.
- A nuclear medicine physician reads the PSMA-PET scan. A medical oncologist reviews the treatment history. In many specialist centers, these two clinicians confer before a written response is sent back to you.
- You receive a written summary that addresses whether your scan meets the PSMA-positive threshold, whether your treatment history fits current eligibility criteria, and whether any further testing is needed before a clear answer is possible.
- If you appear eligible, the team advises on next steps: which treatment center may suit your case, cycle timing, and what monitoring to plan during treatment.
- If you are not clearly eligible, the team outlines what alternatives may apply to your specific situation.
The turnaround time for a preliminary review is typically two to five working days, though complex or borderline cases may take a little longer.
If you are at this stage and want a specialist nuclear medicine team to review your PSMA-PET before you commit to travel, you can request a second opinion through Art of Healing Cancer on whether Lu-177 is right for you. If the scan shows you are not currently a candidate, the review will also point toward what alternatives may exist for your case.
What Happens If Your Scan Is Borderline or Ambiguous
Borderline PSMA-PET scans are more common than most oncology teams discuss openly. The VISION trial, which enrolled 831 patients with PSMA-positive mCRPC and used strict imaging criteria, found that treatment with lutetium Lu-177 vipivotide tetraxetan improved overall survival compared to best supportive care alone (hazard ratio 0.62), as documented in the NCBI clinical reference for this agent. Real-world patients do not always fit those trial criteria as cleanly.
If your scan is borderline, a specialist reviewer may suggest one of the following before confirming eligibility:
- A repeat PSMA-PET scan, particularly if the first was done more than six months ago or at a center that used a different tracer protocol.
- A complementary conventional CT or bone scan to characterize lesions the PSMA-PET did not show clearly.
- A case review by a theranostics multidisciplinary team (MDT) - a group including nuclear medicine, oncology, and radiation oncology - before any final eligibility decision is made.
Borderline does not mean ineligible. It means more information is needed first. Trying to bypass this step by traveling to India and hoping the local team will interpret things more loosely is unlikely to work. Reputable centers in India apply the same imaging thresholds as centers in Europe and North America, because the safety and efficacy data are tied to those thresholds.
If You Are Not Eligible - What Comes Next
Not every man with mCRPC qualifies for Lu-177 PSMA therapy. PSMA expression is not universal. Some tumors carry very low or absent PSMA, which means the radioligand cannot find enough targets to deliver a sufficient radiation dose.
If a remote review finds you are not currently eligible, that is not the end of the conversation. Other options that may apply in mCRPC - depending on your treatment history, tumor genomics, and current health - include taxane-based chemotherapy (if not yet used), PARP inhibitors for patients with BRCA1, BRCA2, or other DNA-repair gene alterations, radium-223 for patients with predominantly bone-only disease, and clinical trials evaluating newer agents. A thorough second opinion should address these alternatives, not simply close a door.
It is also worth knowing that PSMA expression can change over time, particularly under treatment pressure. A scan that shows low PSMA today may look different in several months as the disease evolves. Some patients who are not eligible at one point become eligible later. A reviewing team should advise on whether repeat imaging at a future time point makes sense for your case.
The Cost Argument for Getting the Review Right First
International patients considering India for Lu-177 PSMA therapy typically face a significant cost difference compared to the US or UK. A full treatment course in India is substantially more affordable. But the cost of a trip that turns out to be premature - flights, accommodation, visa fees, local transport, and time away from work for a caregiver - can run to several thousand US dollars before a single cycle of therapy is given. For a full breakdown of what treatment and travel together cost, see our article on Lu-177 PSMA therapy cost in India for international patients.
A remote eligibility review costs far less than that. If it confirms eligibility, you can travel with confidence. If it flags a problem, you have avoided a costly and exhausting journey that would not have led to treatment.
The Prostate Cancer Foundation notes that managing advanced prostate cancer places a significant financial burden on patients, especially those without insurance coverage in their home country. You can read the Prostate Cancer Foundation's summary of the expanded approvals for lutetium Lu-177 vipivotide tetraxetan to understand the current eligibility landscape more fully. A well-structured remote review helps direct limited resources toward actual treatment, not toward a trip that may not yet be warranted.
When to Talk to Your Doctor
Speak with your oncologist as soon as you begin considering a second opinion or international travel for Lu-177 PSMA therapy. Share any remote review findings with your local care team before you travel. Your oncologist can help clarify your treatment history, assist in gathering the right documents, and remain your primary point of contact during and after treatment cycles in India.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
Do I need a new PSMA-PET scan to get a second opinion on Lu-177 eligibility?
Not necessarily. If your PSMA-PET scan was done within the past six months at a reputable imaging centre, most specialist review teams can work from your existing images. You will need the DICOM files - the raw digital scan data - not just the written report. If your scan is older than six months, was done with an uncommon tracer, or was performed at a centre unfamiliar with PSMA imaging, the reviewing team may suggest a repeat scan before giving a definitive answer.
What PSMA-PET finding confirms eligibility for Lu-177 PSMA therapy?
The core requirement, reflected in the VISION trial criteria and current regulatory approvals, is that at least one metastatic lesion must show PSMA uptake greater than normal liver on the PET scan. In addition, no measurable lesion - defined as a lymph node over 2.5 cm, soft-tissue lesion over 1 cm, or bone lesion with a soft-tissue component over 1 cm - should show uptake at or below liver level. A nuclear medicine physician reads the raw scan images to make this determination; the written report alone is not sufficient.
Can I get Lu-177 PSMA therapy in India without having had chemotherapy first?
It depends on which eligibility criteria the treating centre follows. The original VISION trial required prior taxane chemotherapy such as docetaxel, but regulatory agencies including the FDA have expanded approval to include some patients who have not yet received taxane if their oncologist considers it clinically appropriate to delay. Whether a specific Indian centre applies the original or the expanded criteria is something to confirm through a remote eligibility review before you travel.
How long does a remote Lu-177 PSMA eligibility review take?
Most specialist teams complete a preliminary review within two to five working days of receiving your PSMA-PET DICOM files and treatment history. Complex or borderline cases may take a few additional days if the team needs to confer with multiple specialists. You can speed up the process by sending a complete set of documents from the start rather than sharing files in stages.
What if the second opinion team and my current oncologist disagree on eligibility?
This does happen, particularly with borderline PSMA-PET scans. If two specialist teams reach different conclusions, the most useful next step is to understand the specific reasoning behind each view. Ask both teams which lesions they are flagging and why. A third opinion from a theranostics multidisciplinary team - where nuclear medicine, oncology, and radiation oncology review the case together - can help resolve genuine disagreements and give you a clearer path forward.
Is Lu-177 PSMA therapy available in India for patients from the GCC, Africa, or South Asia?
Yes. Several major cancer centres in India offer Lu-177 PSMA therapy to international patients, including those from GCC countries such as UAE, Saudi Arabia, Kuwait, Oman, and Qatar; African countries including Nigeria, Kenya, Ethiopia, and Tanzania; and South Asian neighbours including Bangladesh, Nepal, and Sri Lanka. A remote eligibility review is a practical first step - it determines whether the trip is warranted and gives you the information you need to select the right centre and plan your stay.
